Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × Sugars × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 cyclopia sequence 7 Neoplasms 4 Polycystic Ovary Syndrome 3 Multiple Myeloma 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Vomiting 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pain 2 Neoplasms, Plasma Cell 2 Nausea 2 Leiomyoma 2 Hematologic Diseases 2 Head and Neck Neoplasms 2 Depression 2 Weight Loss 1 Warts 1 Urinary Bladder Neoplasms 1 Testicular Neoplasms 1 Sleepiness 1 Sezary Syndrome 1 Prostatic Intraepithelial Neoplasia 1 Primary Myelofibrosis 1 Peripheral Nervous System Diseases 1 Pediatric Crohn's disease 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Parasomnias 1 Papilloma 1

Interventions

Ipilimumab 79 pembrolizumab 71 Nivolumab 68 aldesleukin 46 Cyclophosphamide 44 Interleukin-2 33 fludarabine phosphate 30 Vemurafenib 29 Dacarbazine 28 trametinib 25 fludarabine 25 dabrafenib 25 Temozolomide 21 Bevacizumab 15 Radiosurgery 14 binimetinib 12 Paclitaxel 12 Introns 12 Interferon alpha-2 12 Carboplatin 11 CTLA-4 Antigen 11 peginterferon alfa-2b 9 montanide ISA 51 9 encorafenib 9 cobimetinib 9 Radiotherapy 9 talimogene laherparepvec 8 atezolizumab 8 Sorafenib 8 spartalizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Dana-Farber Cancer Institute

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡